The benefits of an informed choice model for asymptomatic PSA testing compared with organised prostate cancer screening programmes are questionable at best.5 Current UK guidance for asymptomatic PSA testing lacks any nuance with regards to testing men at higher risk, nor does it recognise there is a point in terms of age at which the harms of asymptomatic PSA testing outweigh the benefits.4 In this study, almost half of those patients where prostate cancer was detected through asymptomatic PSA testing were in men aged ≥70 years. The gene discussed is KLK3; the disease is prostate carcinoma.